While most current Alzheimer’s treatments focus on beta-amyloid plaques, new research targets early-stage DNA damage and chronic neuroinflammation as critical drivers of the disease. In preclinical mouse models, the drug KCL-286 — a compound already proven safe in human spinal cord injury trials — successfully activated DNA repair genes, healed double-strand DNA breaks in neurons, and significantly reduced neuroinflammation. By addressing these foundational pathological processes, KCL-286 has the potential to slow Alzheimer’s progression rather than merely managing symptoms, offering a promising candidate for early or even asymptomatic intervention. Additionally, the article highlights a separate breakthrough in late-stage care, noting that psilocybin successfully restored speech and motor control in a patient after a decade of battling the disease.

A drug, that has previously been shown to be safe and tolerated by humans, reduces multiple disease-linked features of Alzheimer’s in a mouse model of the disease.